Is Eli Lilly Stock Running out of Steam?
2026-08-03 17:29
•David Jagielski, Cpa •The Motley Fool
••• • Axe Cap view
Eli Lilly’s Surge: Buy the Dip or Time to Pause?
Eli Lilly’s strong growth from GLP-1 drugs faces a tough valuation and emerging risks.
Eli Lilly has been a standout performer largely thanks to its GLP-1 drugs like Mounjaro and Zepbound. With a 56% revenue jump in Q1, there’s no denying the strength of its current pipeline, especially retatrutide, which could bring in billions. But trading at roughly 40 times earnings, this stock is priced for perfection. The recent 11% pullback may look like a bargain, yet it’s a nod to rising concerns: competition, regulatory hurdles, or slower uptake could throw a wrench in growth expectations. For JSE investors, Lilly is worth watching through the USD/ZAR lens—strong dollar strength tends to boost share price in rand terms, but any rand weakness also impacts portfolio returns. It’s a high-growth story, but one that demands caution given its stretched valuation and sector volatility. this is just our opinion and not financial advice
Consider waiting for a clearer entry point or trimming if you hold, especially if USD/ZAR shows signs of weakening. Focus on risk management rather than chasing the peak.
- LLY
- USD/ZAR
- competition in GLP-1 drug market
- regulatory changes affecting drug approval and pricing
6/10
Eli Lilly has surged over 300% in five years driven by blockbuster GLP-1 drugs Mounjaro and Zepbound, which generated 56% revenue growth in Q1. While the stock trades at a premium 40x earnings valuation, analysts argue it remains justified given upcoming pipeline catalysts like retatrutide (projected $3.8B revenue by 2030) and potential new indications for GLP-1 drugs. The stock is down 11% from highs, presenting a potential entry point for long-term investors.
Our take is based on reporting first published by The Motley Fool.